Clinical Trials

47 enrolled

Leukemia, Myeloid, Acute

NCT07464951 2026-05-27

CART123

30 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT04628026 2026-05-26

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

650 enrolled

Leukemia, Myeloid, Acute

NCT05564390 2026-05-26

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT06945042 2026-05-26

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Phase NA Recruiting

120 enrolled

Financial Stress, Leukemia, Myeloid, Acute

NCT07607418 2026-05-26

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

Classical hematologyOther hematologic neoplasm

20 enrolled

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT02727803 2026-05-22

Personalized NK Cell Therapy in CBT

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

100 enrolled

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

MyeloidOther hematologic neoplasmSarcoma

100 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT04493164 2026-05-22

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

30 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05362773 2026-05-22

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

130 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT06326021 2026-05-22

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

27 enrolled

Leukemia, Myeloid, Acute

NCT06763341 2026-05-22

A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

12 enrolled

Leukemia, Myeloid, Acute

NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

508 enrolled

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT03629171 2026-05-20

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute

NCT03728335 2026-05-20

Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation

35 enrolled

Leukemia, Myeloid, Acute

NCT04774393 2026-05-20

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

84 enrolled

Leukemia, Myeloid, Acute

NCT05360160 2026-05-20

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

43 enrolled

Leukemia, Myeloid, Acute

NCT07211958 2026-05-20

REVEAL-ND NPM1

468 enrolled

Leukemia, Myeloid, Acute

NCT05183035 2026-05-19

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

130 enrolled

Leukemia, Myeloid, Acute

NCT07155226 2026-05-19

MOMENTUM

84 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07591649 2026-05-19

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

18 enrolled

Leukemia, Myeloid, Acute

NCT03326921 2026-05-18

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

24 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

15 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05133882 2026-05-15

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

133 enrolled

Leukemia, Myeloid, Acute

NCT05554393 2026-05-15

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

153 enrolled

Leukemia, Myeloid, Acute

NCT06191978 2026-05-15

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

40 enrolled

Leukemia, Myeloid, Acute

NCT06285890 2026-05-15

Phase I Study of HC-7366 for Acute Myeloid Leukemia

18 enrolled

Leukemia, Myeloid, Acute

NCT06445907 2026-05-15

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

32 enrolled

Leukemia, Myeloid, Acute

NCT06928662 2026-05-15

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

36 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05429632 2026-05-14

MO-TRANS

366 enrolled

Leukemia, Myeloid, Acute

NCT06222580 2026-05-14

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

30 enrolled

Leukemia, Myeloid, Acute

NCT07566377 2026-05-14

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

71 enrolled

Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07583888 2026-05-14

VABu Conditioning in Elderly AML HSCT

Phase 2/3 Recruiting

20 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT07588360 2026-05-14

Haplo-Cord HSCT for AML/MDS

Phase NA Recruiting

180 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05401097 2026-05-13

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

125 enrolled

Leukemia, Myeloid, Acute

NCT06484062 2026-05-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

54 enrolled

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06635681 2026-05-13

DAV-AML-2024

380 enrolled

Leukemia, Myeloid, Acute

NCT07584889 2026-05-13

CAR-p40-T

LymphoidOther hematologic neoplasm

10 enrolled

Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07007312 2026-05-12

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

1,300 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07044687 2026-05-12

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

Phase 4 Recruiting

100 enrolled